The aim of the study was to identify factors associated with the failure of cardiologists to change to a different antihypertensive class or to add a new antihypertensive class in high coronary risk patients with uncontrolled hypertension. Among these patients, a new antihypertensive class was less likely to be added in the presence of controlled diastolic blood pressure (BP), previous stroke or treated dyslipidemia or diabetes mellitus.
In secondary prevention, the difficulty in controlling hypertension has been demonstrated. 1 Crosssectional surveys conducted in the Europe show that about 30% of patients admitted for unstable angina or myocardial infarction are discharged from the hospital with uncontrolled hypertension 2 and that about 50% of such patients have high BP 6 months after hospitalization. 3 Determining the factors underlying these disappointing results is an important issue. We have previously found that a large proportion of uncontrolled hypertensive patients at high cardiovascular risk were on monotherapy. 1 The aim of this study was to characterize factors related to absence of change to a different antihypertensive class or add a new antihypertensive class in treated, uncontrolled hypertensives seen by cardiologists in the outpatient setting.
Individual data of patients recruited to participate in two cross-sectional surveys on cardiovascular prevention: the ELICOEUR study 4 and the ELIAGE study, 5 respectively, conducted in middle-aged (patients aged 35À69 years) and in elderly patients (X70 years of age) were analysed. Both studies were conducted in France in 2003, in patients with previous cardiovascular disease or at high risk of coronary heart disease and seen by his or her cardiologist for a routine follow-up visit and not a separate study visit. In these two studies, all regions of France were represented and the investigators were instructed to recruit the first four patients seen at their office with a previous history of cardiovascular disease or with major cardiovascular risk factors. Age, smoking habits, diabetes mellitus, antihypertensive drug regimens and cardiovascular history were reported. For diuretic, b-blocker, angiotensin converting enzyme inhibitor, angiotensin receptor blocker, calcium channel blocker and other antihypertensive agents (that is, central acting drug and a-blocker) the investigators were instructed to note if these drugs were previously prescribed, if they were stopped or if they were introduced at the time of the office visit. Then, the cardiologists were instructed to measure BP as they usually did. The current analysis was performed in patients with reported history of treated hypertension currently taking at least one antihypertensive medication.
Controlled hypertension and stages of uncontrolled hypertension were defined with respect to European guidelines. 6 Uncontrolled hypertension was therefore defined as a BPX140 mm Hg systolic or X90 mm Hg diastolic, on the day of the office visit.
Individual data of patients in the ELICOEUR study 4 and ELIAGE study 5 were analysed separately. Patients were categorized according to BP control. Additionally, patients were categorized by the addition or the modification of at least one antihypertensive drug class at the study visit. The relations between BP control, clinical characteristics, and BP profile according to the decision to add or change to a different antihypertensive class were assessed in bivariate analysis and then using a multivariable logistic regression: variables found to be significant in bivariate analyses were introduced in the multivariate models. Additionally, all the models were systematically adjusted for age and sex. Statistical analyses were performed on SAS statistical software (SAS/STAT User's Guide, release 6.12. Cary, NC, USA; SAS Institute Inc., 1997). Po0.05 was considered as statistically significant.
Of Abbreviations: CHD, coronary heart disease; CHF, coronary heart failure; ISH, isolated systolic hypertension; PAD, peripheral heart disease; SBP, systolic blood pressure. Percentages are in parentheses. *Po0.001; **Po0.05; ***Po0.0001. a Coronary heart disease: patients with history of myocardial infarction, angina (stable or unstable) or coronary revascularization. b Comparison performed between monotherapy, two-and three-drug combination therapy or more.
(13.65%) patients in ELIAGE and a different antihypertensive class was added in 122 (15.58%) patients in ELICOEUR and in 100 (9.96%) patients in ELIAGE. In both studies, the middle-aged and elderly-population groups, age did not significantly differ among patients in whom antihypertensive treatment was changed or intensified from those whose therapy was unchanged ( Table 1 ). The number of treated risk factors in ELICOEUR, prior stroke in ELIAGE and both in ELIAGE and ELI-COEUR studies, the number of antihypertensive agents previously prescribed and a controlled diastolic BP were all negatively associated with these decisions. Similar results were observed after adjustment for confounders. In patients included in ELICOEUR (respectively in ELIAGE) with uncontrolled hypertension, diuretics and angiotensin converting enzyme inhibitors (respectively diuretics and calcium channel blocker) were the antihypertensive agents the most frequently added. In the two classes of age, angiotensin converting enzyme inhibitors and calcium channel blockers were the antihypertensive agents the most frequently stopped.
There are four principal findings from this study concerning the likelihood to change to or add a different antihypertensive class in these high-risk patients with uncontrolled BP. Surprisingly, a new antihypertensive class was less likely to be added in patients with other treated risk factors. This was also true in patients with previous history of stroke. Finally, controlled diastolic BP (o90 mm Hg) was associated with a lesser likelihood of changing or adding a new antihypertensive class in patients with elevated systolic blood pressure (SBP) (X140 mm Hg).
Thus, our data may contribute to explain why in apparently healthy subjects 6 like in patients with coronary disease 7 more than half of uncontrolled hypertensives have isolated systolic hypertension. Also the current data contribute to explain why hypertension control was poorer in patients with previous stroke than in patients with previous myocardial infarction. 8 Finally, these results may account for the intriguing negative correlation reported in large observational trials between the presence of associated risk factors and hypertension control. 1 Concerns about an excessive fall in BP could contribute to this attitude especially in stroke patients, 9 although a large body of evidence reinforces the importance of tight BP control in secondary stroke prevention. 10, 11 Also, it is likely that cardiologists are reluctant to increase the number of pills to take every day in patients with two or more cardiovascular risk factors since patient difficulty with polypharmacy is pointed out as a barrier to adherence to treatment. 12 Regarding these results, the limitations of the study are non standardized BP recording, lack of record of control of other risk factors, stroke subtype, time from stroke: all factors that could also influence practitioner's decision. Also the changes in the dose of antihypertensive agents were not recorded. Therefore, the proportion of patients with uncontrolled hypertension in whom antihypertensive treatment was adjusted is underestimated. However, as stated by European guidelines, most patients with hypertension will require two or more antihypertensive medications to achieve their BP goals. Thus, it is of paramount importance to identify factors associated with the failure of cardiologists to change to a different antihypertensive class in daily practice. In summary, practitioners are reluctant to add or change to a different antihypertensive class in patients previously treated for other risk factors or by antihypertensive combination therapy and in patients with history of stroke and/or controlled diastolic BP. These results are a matter of concern with respect to the benefit, which would be drawn from a strict BP control in these populations.
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